ERBB2 and urinary bladder cancer: Trastuzumab emtansine (TDM1), an ADC comprising the anti-HER2 antibody rastuzumab, has received FDA approval for treating HER2-positive bladder cancer patients who have previously undergone paclitaxel/rastuzumab therapy.